Abstract: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.

Abstract: An aqueous injectable solution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Abstract: The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.

Abstract: A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.

Abstract: An aqueous injectable solution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Abstract: An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Abstract: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.

Abstract: A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt at least one of the acids for forming the salts in free acid form.

Abstract: A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution containing the first peptide salt with a mixed bed ion exchanger, wherein the mixed bed ion exchanger has strongly acidic cations and strong anion exchangers; separating the mixed bed ion exchanger from the diluent solution; contacting the diluent solution with an acid having a pharmaceutically acceptable anion, thereby forming an acid addition salt of the peptide having the pharmaceutically acceptable anion; adding an adjuvant to the diluent solution; and separating the diluent from the diluent solution. The invention also relates to a method for treatment of benign prostate hyperplasia, myoma, or endometriosis with the composition.

Abstract: A method for producing peptide salts, including reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger, with a mixture of an acid and a basic ion exchanger during the formation of a free basic peptide, and then separating the ion exchanger and then the free basic peptide, with an inorganic or organic acid, and then forming the desired acid addition salt of the peptide, and removing the diluent.

Abstract: An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Abstract: A method for producing peptide salts, including reacting an acid addition salt of a basic starting peptide in the presence of a diluent in a mixed bed ion exchanger, with a mixture of an acid and a basic ion exchanger during the formation of a free basic peptide, and then separating the ion exchanger and then the free basic peptide, with an inorganic or organic acid, and then forming the desired acid addition salt of the peptide, and removing the diluent.

Abstract: The invention relates to pharmaceutical administration forms suitable for parenteral administration, which contains [sic] peptides prone to aggregation in the form of their acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and additionally comprises [sic] one of the acids mentioned as free acid.

Abstract: The boron concentration can be measured without intervention into the cooling circuit of a nuclear power station. A mobile emitter and a mobile receiver are provided, with the interposition of at least one coolable region, for placement on a coolant-carrying component of the cooling circuit.

Abstract: The invention relates to a welding band for welding synthetic resin film including a steel band, which is coated in its end parts with a thin copper layer. To attain the aim of improving the working life of such a welding band, the thin copper layer is covered with an even thinner metallic layer, preferably of nickel.

Abstract: In a high-pressure cleaning apparatus with a high-pressure pump for a cleaning liquid connected on the suction side to a preliminary tank with a feed pipe for cleaning liquid and having in the pressure pipe a bypass pipe branching off from this pressure pipe and leading to the preliminary tank, and with an electromotor driving the high-pressure pump and having a coolant pipe through which cleaning liquid flows, in order to also ensure effective cooling of the electromotor in the recirculation mode without loss of coolant, it is proposed that the feed pipe to the preliminary tank have a greater conveying capacity than the coolant pipe and that the coolant pipe lead into the preliminary tank in which there is a means for limiting the filling level.

Abstract: Ion exchange medium in a water softening system is regenerated cyclically, in response to both a preset timer and a metering device responsive to the degree of hardness of the untreated water and the degree of exhaustion of the ion exchange medium, by slowly feeding regenerating medium, prepared during the softening phase by the metering device, counter current to flow during softening at a rate so as not to disturb the exchange medium and to prevent substantial mixing of the regenerating medium with the water being displaced.